Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis?

Emmanouil Sinakos, Keith D. Lindor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Eighty percent of patients with primary sclerosing cholangitis (PSC) have IBD. In this setting, IBD has been shown to have some unique characteristics, including an increased risk of colorectal cancer (CRC). Currently, there are no reports of a medical therapy that can be able to halt PSC progression. Ursodeoxycholic acid (UDCA) has been shown to exert some beneficial effects as measured by liver biochemistry. In addition, UDCA has been suggested to act as a chemopreventive agent against CRC in patients with PSC and IBD. However, a recent randomized, controlled, high-dose UDCA trial failed to demonstrate improvement in survival and was associated with increased rates of serious adverse events; the presence of IBD did not have any effect on outcomes. Taking all the available data into consideration, we suggest that UDCA cannot be generally be recommended in patients with PSC and IBD.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Inflammatory Bowel Disease
Subtitle of host publicationNew Challenges: Second Edition
PublisherWiley-Blackwell
Pages156-158
Number of pages3
ISBN (Print)9781444334548
DOIs
StatePublished - Jan 30 2012
Externally publishedYes

Keywords

  • Chemoprevention
  • Colorectal carcinoma
  • Inflammatory bowel disease
  • Primary sclerosing cholangitis
  • Treatment
  • Ulcerative colitis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis?'. Together they form a unique fingerprint.

  • Cite this